J1670 HCPCS Level II code: Injection, tetanus immune globulin, human, up to 250 units

J1670 is the HCPCS code for “Injection, tetanus immune globulin, human, up to 250 units” in CMS’s October 2026 release, in effect from Oct 1, 2026.

Official description

J1670

Injection, tetanus immune globulin, human, up to 250 units

Short description: Tetanus immune globulin inj

HCPCS · United States

Medicare details

The indicators CMS publishes with J1670 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage
Special coverage instructions apply
Medicare pricing
Drugs
ASC
Approved for ambulatory surgical centers
Type of service
Medical care; Lump sum purchase of DME, prosthetics, orthotics
BETOS category
Other drugs
Added
Jan 1, 1986

Where J1670 sits

  1. 1J codesDrugs administered other than orally
  2. 2Active code J1670Injection, tetanus immune globulin, human, up to 250 units

Source and release

Data release
HCPCS Level II · October 2026
Effective date
Oct 1, 2026
Publisher
CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

Frequently asked questions

What does HCPCS code J1670 mean?

J1670 is the HCPCS code for “Injection, tetanus immune globulin, human, up to 250 units” in CMS’s HCPCS Level II October 2026 release.

Does Medicare cover J1670?

CMS lists J1670’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.